United States - English - NLM (National Library of Medicine)

piramal healthcare uk limited - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection, usp is indicated:        •as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age        •to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu        •to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection, usp is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate injection, usp is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate injection, usp have been reported [see warnings and precautions (5.4 )] . the use of 10 ml cisatracurium besylate injection, usp multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth w

United States - English - NLM (National Library of Medicine)

piramal healthcare uk limited - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection, usp is indicated:        •as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age        •to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu        •to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection, usp is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate injection, usp is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate injection, usp have been reported [see warnings and precautions (5.4 )] . risk summary there are no adequate and well-controlled studies of cisatracurium besylate in pregnant women. animal studies conducted in rats administered cisatracur

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as kalceks a.s. - atracurium besilate 10 mg/ml - solution for injection/infusion - 10 mg/ml - atracurium besilate 10 mg/ml - atracurium

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as kalceks a.s. - atracurium besilate 10 mg/ml - solution for injection/infusion - 10 mg/ml - atracurium besilate 10 mg/ml - atracurium

United States - English - NLM (National Library of Medicine)

piramal critical care inc - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: • as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age • to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu • to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. • cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate injection have been reported [see warnings and precautions ( 5.4)] . risk summary there are no available clinical trial data on cisatracurium use in pregnancy to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal

Kenya - English - Pharmacy and Poisons Board

questa care inc. c/o surgilinks ltd p.o. box 5124 madonna road san luis obispo ca - atracurium besylate usp - injection - atracurium besylate usp 10mg - peripherally acting muscle relaxants:

United States - English - NLM (National Library of Medicine)

caplin steriles limited - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: • as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age • to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu • to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older. limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. cisatracurium besylate is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate have been reported [see warnings and precautions (5.4)] . the use of 10 ml cisatracurium besylate multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains ben

Canada - English - Health Canada

omega laboratories limited - cisatracurium (cisatracurium besylate) - solution - 2mg - cisatracurium (cisatracurium besylate) 2mg - neuromuscular blocking agents

Canada - English - Health Canada

omega laboratories limited - cisatracurium (cisatracurium besylate) - solution - 2mg - cisatracurium (cisatracurium besylate) 2mg - neuromuscular blocking agents

Canada - English - Health Canada

pfizer canada ulc - cisatracurium (cisatracurium besylate) - solution - 2mg - cisatracurium (cisatracurium besylate) 2mg - neuromuscular blocking agents